Establishment of a rat model of nonalcoholic steatohepatitis and histopathological changes of the pancreas and the kidney
-
摘要: 目的探讨非酒精性脂肪性肝炎大鼠模型肝外脏器胰腺、肾脏的组织学病理变化情况。方法将20只SD大鼠中的6只首先按完全随机配对分配到观察组(B组),将剩下的14只按体质量配对成7个区组,最后将每个区组中的1只大鼠按随机数字表分配到实验组(C组),其余7只为对照组(A组)。B组和C组给予高脂饮食,A组给予普通饮食。B组于实验第4、8、12周各处死2只,提取肝脏组织行HE染色,显微镜下观察肝脏病理切片是否达到脂肪性肝炎,第12周末建模成功(提示C组建模成功)。处死A组和C组全部大鼠,分别检测血清学指标ALT、AST、GGT、TG、TC、LDL、GLU、INS、HOMA-IR,取肝脏组织行HE染色;胰腺组织行HE染色观察大鼠胰腺腺泡和胰岛变化情况;肾脏组织行PAS染色,免疫组织化学desmin蛋白染色观察肾小球和足细胞desmin表达情况。计量资料2组间比较采用t检验。结果 C组大鼠病理评分及血清ALT、GGT、LDL、TG、TC、GLU、INS、HOMAIR水平均高于A组(t值分别为4. 67、2. 83、2. 34、4. 58、4. 78、3. 00、2. 97、3. 80、4. 10,P值均...
-
关键词:
- 非酒精性脂肪性肝炎 /
- 大鼠,Sprague-Dawley /
- 胰腺 /
- 肾脏 /
- 组织和显徽镜检结果
Abstract: Objective To establish a rat model of nonalcoholic steatohepatitis,and to investigate the histopathological changes of the extrahepatic organs of the pancreas and the kidney. Methods A total of 20 Sprague-Dawley rats were selected,among which 6 were randomly selected as the observation group(group B). The remaining 14 rats were paired into seven groups according to body weight,then a random number table was used to select 1 rat from each group and assign them into the experimental group(group C),and the remaining 7 rats were assigned to the control group(group A). The rats in groups B and C were given high-fat diet,while those in group A were given a normal diet. In group B,two rats each were killed at weeks 4,8,and 12 of the experiment,liver tissue was extracted for HE staining,and liver pathological sections were observed under a microscope to see whether steatohepatitis was achieved. The model was successfully established at the end of week 12. All rats in groups A and C were sacrificed,and the serological markers alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma-glutamyl transpeptidase(GGT),triglyceride(TG),total cholesterol(TC),low-density lipoprotein(LDL),glucose(GLU),insulin(INS),and homeostasis model assessment of insulin resistance(HOMA-IR) were measured. HE staining was performed for liver tissue and pancreatic tissue to observe the changes in pancreatic acini and pancreatic islets. PAS staining was performed for kidney tissue,and immunohistochemical desmin-staining was performed to observe the expression of desmin in glomerular podocytes. The t-test was used for comparison of continuous data between two groups. Results Compared with group A,group C had significantly higher pathological score and serum levels of ALT,GGT,LDL,TG,TC,GLU,INS,and HOMA-IR(t = 4. 67,2. 83,2. 34,4. 58,4. 78,3. 00,2. 97,3. 80 and 4. 10,all P < 0. 05). Liver pathological changes were observed in the high-fat group from week 4 to week 12,i. e.,the lobular structure was gradually destroyed,the small fat vacuoles in the cytoplasm of the hepatocytes gradually developed into large fat vacuoles,and inflammatory cell infiltration gradually appeared in the portal area. Pancreatic pathological changes were observed in the high-fat group at the end of week 12,i. e.,apoptosis and atrophy of pancreatic acinar cells were observed,and no significant abnormalities were observed in pancreatic islet cells. Renal pathological changes were observed in the high-fat group at the end of week 12,i. e.,therewere significant increases in the substances with positive PAS staining results,the glomerular volume,and the thickness of the glomerular capillary basement membrane,with disordered arrangement of capillary loops,hyperplasia of the mesangial area,swelling of renal tubular epithelial cells,and stenosis of some lumens. Immunohistochemical staining showed an increase in the expression of desmin in glomerular podocytes in the high-fat group. Conclusion A rat model of nonalcoholic steatohepatitis is successfully established by high-fat diet.Nonalcoholic steatohepatitis in rats may lead to apoptosis and atrophy of pancreatic acinar cells,increase in glomerular volume,thickening of the capillary basement membrane,mesangial hyperplasia,and podocyte injury. -
[1] GUO YY,SUI CH,LUO QQ,et al. Dynamic fluctuation of blood glucose and its effects on prognosis in patients with nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus[J]. J Clin Exp Med,2019,18(11):1173-1175.(in Chinese)郭郁郁,隋春华,罗清琼,等.非酒精性脂肪性肝病合并2型糖尿病患者血糖动态波动水平及其对预后的影响[J].临床和实验医学杂志,2019,18(11):1173-1175. [2] LI AA,AHMED A,KIM D. Extrahepatic manifestations of nonalcoholic fatty liver disease[J]. Gut Liver,2019.[Epub ahead of print] [3] ZHOU F,ZHOU J,WANG W,et al. Unexpected rapid increase in the burden of nonalcoholic fatty liver disease in china from 2008 to 2018:A systematic review and Meta-analysis[J]. Hepatology,2019,26(4):972-976. [4] ALLEN AM,HICKS SB,MARA KC,et al. The risk of incident extrahepatic cancers is higher in nonalcoholic fatty liver disease than obesity-a longitudinal cohort study[J]. J Hepatol,2019,26(4):698-703. [5] LI JX,CHEN J,WANG YL. Consensus on the diagnosis and treatment of non-alcoholic fatty liver diseases based on integrated Chinese and western medicine(2017)[J]. Chin J Integr Trad West Med Dig,2017,25(11):805-811.(in Chinese)李军祥,陈誩,王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811. [6] WU JY,ZHENG L,MO JF,et al. Regulation of N-acetylcysteine on peripheral circulatory and hepatic myeloid-derived suppressor cells in non-alcoholic fatty liver disease mice[J]. Chin J Clin Pharmacol Ther,2019,24(9):989-996.(in Chinese)吴加元,郑丽,莫娟芬,等.N-乙酰半胱氨酸调控非酒精性脂肪性肝病小鼠外周循环及肝脏局部髓源抑制细胞的研究[J].中国临床药理学与治疗学,2019,24(9):989-996. [7] PEVERILL W,POWELL L,SKOIEN R. Evolving concepts in the pathogenesis of NASH:Beyond steatosis and inflammation[J]. Int J Mol Sci,2014,15(5):8591-8638. [8] HASAN JANI ROUSHAN MR,HAJIAHMADI M,SHAFAIE S.Histopathological features of liver and its relation to serum transaminase levels in 91 cases of anti-HBe-positive chronic hepatitis B[J]. Int J Clin Pract,2005,59(7):791-794. [9] SUI L. Application and evaluation of serum AFU,LAP and GGT in the diagnosis of early primary liver cancer[J]. Chin J Lab Diag,2016,20(7):1088-1089.(in Chinese)隋菱.血清AFU、LAP和GGT联合检测在早期原发性肝癌诊断中的应用与评价[J].中国实验诊断学,2016,20(7):1088-1089. [10] GAO HF,ZHAO QJ,WANG J. Application of serum alphafetoprotein,alpha-l-fucosidase,5'-nucleotide enzyme and gamma-glutamyl transpeptidase in early diagnosis of hepatocellular carcinoma[J]. Cancer Res Clin,2016,28(8):519-522.(in Chinese)高海锋,赵秋剑,王静,等.血清甲胎蛋白、α-L-岩藻糖苷酶、5'-核苷酸酶和γ-谷氨酰转肽酶在肝细胞癌早期诊断中的应用[J].肿瘤研究与临床,2016,28(8):519-522. [11] TANAKA N,KIMURA T,FUJIMORI N,et al. Current status,problems,and perspectives of non-alcoholic fatty liver disease research[J]. World J Gastroenterol,2019,25(2):163-177. [12] PARK H,DAWWAS GK,LIU X,et al. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease:A propensity-matched cohort study[J]. J Intern Med,2019,286(6):711-722. [13] KAYSEN GA. New insights into lipid metabolism in chronic kidney disease:What are the practical implications?[J]. Blood Purif,2009,27(1):86-91. [14] FUNK J,OTT V,HERRMANN A,et al. Semiautomated quantitative image analysis of glomerular immunohistochemistry markers desmin,vimentin,podocin,synaptopodin and WT-1in acute and chronic rat kidney disease models[J]. Histochem Cell Biol,2016,145(3):315-326. [15] WELSH GI,HALE LJ,EREMINA V,et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function[J]. Cell Metabolism,2010,12(4):329-340. [16] IRSIK DL,CHEN JK,BRANDS MW. Chronic renal artery insulin infusion increases mean arterial pressure in male Sprague Dawley rats[J]. Am J Physiol Renal Physiol,2017,14(3):374-378. [17] SALEEM MA. The human glomerular podocyte is a novel target for insulin action[J]. Diabetes,2005,54(11):3095-3102. [18] FUKUI H,HORI M,FUKUDA Y,et al. Evaluation of fatty pancreas by proton density fat fraction using 3-T magnetic resonance imaging and its association with pancreatic cancer[J].Eur J Radiol,2019,118:25-31. [19] DELLA CORTE C,MOSCA A,MAJO F,et al. Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease:More than ectopic fat[J]. Clin Endocrinol(Oxf),2015,83(5):656-662. [20] YUAN BB,TAN YE,LIU JJ,et al. Current status of the research on nonalcoholic fatty pancreatic disease[J]. J Clin Hepatol,2019,35(5):1161-1164.(in Chinese)袁贝贝,谭玉娥,刘京京,等.非酒精性脂肪性胰腺病的研究现状[J].临床肝胆病杂志,2019,35(5):1161-1164. [21] WANG CY,OU HY,CHEN MF,et al. Enigmatic ectopic fat:Prevalence of nonalcoholic fatty pancreas disease and its associated factors in a chinese population[J]. J Am Heart Assoc,2014,3(1):e297-e303. [22] OU HY,WANG CY,YANG YC,et al. The association between nonalcoholic fatty pancreas disease and diabetes[J].PLo S One,2013,8(5):e62561. [23] CHEN D,LIESS C,POLJAK A,et al. Phenotypic characterization of insulin-resistant and insulin-sensitive obesity[J].J Clin Endocrinol Metab,2015,100(11):4082-4091. [24] TUSHUIZEN ME,BUNCK MC,POUWELS PJ,et al. Pancreatic fat content and beta-cell function in men with and without type 2diabetes[J]. Diabetes Care,2007,30(11):2916-2921. 期刊类型引用(31)
1. 丁辉,苏雪梅,张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 . 百度学术
2. 王慧敏,谭炳芹,王万鹏,吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 . 百度学术
3. 张璨,张欢欢,高飞,任佩佩,罗明阳,闫冬,王馨,王莹莹,曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 . 百度学术
4. 李述美,刘冰,刘仁伟,杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 . 百度学术
5. 安薪宇,乔杰,胡灵溪,王荣琦,南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . 百度学术
6. 张航,刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
7. 马杨青,范海纳,孙鑫,刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
8. 张欢,雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 . 百度学术
9. 陈腾千,姜丽华,张生君,蒋义贵,罗佳,胡永敏,尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 . 百度学术
10. 李雨蓉,姚明解,王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 . 百度学术
11. 刘燕娜,姚明解,郑素军,陈香梅,刘向祎,胡鹏,欧启水,窦晓光,陈红松,段钟平,侯金林,南月敏,高志良,徐小元,庄辉,鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 . 百度学术
12. 裴倩云,孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 . 百度学术
13. 王鹏飞,刘树红,钱相君,翟相威,文夏杰,姚明解,赵景民,鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 . 百度学术
14. 郑伟明,罗翠转,卢金英,骆晓豪,刘浩,梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 . 百度学术
15. 庄云英,张海燕,曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 . 百度学术
16. 刘燕娜,姚明解,鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 . 百度学术
17. Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 . 百度学术
18. 罗双艳,何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 . 百度学术
19. 高伟,高虹,尹春梅,杨森林,范晓红,刘春亮,李雪卿,贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 . 百度学术
20. 王一奇,苑喜微,李冬冬,汤玉会,薛宁宁,崔璐瑶,刘领弟,南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 . 百度学术
21. 张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 . 百度学术
22. 刘沁雨,常越,张青,丁玉平,李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 . 百度学术
23. 翟相威,刘树红,姚明解,钱相君,文夏杰,许强,赵景民,鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 . 百度学术
24. 范旭,单珊,刘立伟,贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 . 百度学术
25. 范旭,单珊,刘立伟,贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 . 百度学术
26. 刘沁雨,常越,张文,张青,卢诚震,李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 . 百度学术
27. 马玲玉,甄一宁,罗云萍,段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 . 百度学术
28. 刘沁雨,常越,张青,丁玉平,李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 . 百度学术
29. 李佳娜,郑瑞琦,李娜,胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
30. 王春艳,纪冬,马丽君,陈松海,王晶晶,邵清,陈国凤,韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 . 百度学术
31. 宋莹,李世朋,焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 . 百度学术
其他类型引用(12)
-